Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled time : 22:00 save search
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market to Showcase Significant Growth at a CAGR of 15% by 2032 | DelveInsight
Published: 2024-04-15 (Crawled : 22:00) - prnewswire.com
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: -0.17%
H: 1.41%
C: -0.22%
t-cell for therapy growth market
Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-02-23 (Crawled : 22:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.28%
H: 0.0%
C: 0.0%
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: 2.07%
H: 5.02%
C: 4.92%
carvykti chmp biotech positive treatment therapy
Nevro Announces Consensus Statement Supporting High-Frequency (10 kHz) Spinal Cord Stimulation Therapy for Refractory Painful Diabetic Neuropathy
Published: 2024-02-01 (Crawled : 22:00) - prnewswire.com
NVRO | $12.07 -2.03% 0.0% 390K
|
Health Technology
|
| O: -1.45%
H: 1.36%
C: -4.18%
therapy diabetic
CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight
Published: 2024-01-23 (Crawled : 22:00) - prnewswire.com
ACLX | $51.67 -5.19% -5.48% 740K
|
|
| O: 1.59%
H: 1.14%
C: -1.42%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.61%
H: 1.52%
C: 0.03%
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: 1.57%
H: 4.94%
C: 1.54%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.29%
H: 0.15%
C: -1.95%
BEAM | $23.9 -1.69% -1.72% 4.5M
|
Health Technology
|
| O: 1.88%
H: 0.88%
C: -2.79%
t-cell therapy growth study market
AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.77%
H: 0.17%
C: -1.65%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
RGNX | $15.67 -2.73% -2.87% 570K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
ADVM | $11.34 1.7% 1.68% 140K
|
Health Technology
|
| O: -0.69%
H: 2.32%
C: -0.12%
therapy growth study market
Gene Therapy Global Market is Projected to Grow at a CAGR of ~19% by 2028, Predicts DelveInsight
Published: 2024-01-12 (Crawled : 22:00) - prnewswire.com
TGTX | $13.79 -1.43% -1.45% 3.7M
|
Health Technology
| Email alert
Add to watchlist
VRTX | News | $394.43 0.24% 0.24% 1.3M
|
Health Technology
| Email alert
Add to watchlist
RARE | News F | $42.37 -2.33% -2.38% 680K
|
Health Technology
| Email alert
Add to watchlist
SLDB | $8.7 -6.05% -6.44% 110K
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
| Email alert
Add to watchlist
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
DTIL | $9.75 -9.05% -9.95% 170K
|
Health Technology
| Email alert
Add to watchlist
global therapy market
BRP Group, Inc.’s AHT Insurance Launches First-Ever Psychedelic Therapy Malpractice Insurance Program
Published: 2023-12-12 (Crawled : 22:00) - baldwinriskpartners.com
BRP | $27.58 2.87% 2.79% 270K
|
Finance
|
| O: -0.57%
H: 7.42%
C: 6.32%
program insurance therapy
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
BLUE | $1.02 7.03% 6.11% 8.2M
|
Health Technology
|
| O: 6.03%
H: 8.43%
C: -43.92%
disease cell commercial therapy
Genentech’s Kadcyla Is the First Targeted Therapy to Show Significant Overall Survival Benefit in People With HER2-Positive Early-Stage Breast Cancer With Residual Invasive Disease After Neoadjuvant Treatment
Published: 2023-12-08 (Crawled : 22:00) - biospace.com/
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
first disease breast cancer treatment therapy show
Time for a Renaissance in Gene Editing and Gene Therapy
Published: 2023-11-15 (Crawled : 22:00) - poseida.com
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -0.45%
H: 0.91%
C: -2.27%
therapy
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates
Published: 2023-11-13 (Crawled : 22:00) - globenewswire.com
PROK | $2.045 -14.79% -17.36% 780K
|
|
| O: 13.75%
H: 2.75%
C: -16.48%
rmcl-002 react renal positive cell trial therapy diabetic
Sarepta Therapeutics Announces Topline Results from EMBARK, a Global Pivotal Study of ELEVIDYS Gene Therapy for Duchenne Muscular Dystrophy
Published: 2023-10-30 (Crawled : 22:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 1.05%
H: 1.86%
C: -0.28%
global topline therapeutics duchenne therapy results study
Thermo Fisher Scientific Helps Accelerate Cell Therapy Manufacturing with a Next-Generation Platform of Gibco™ CTS™ Detachable Dynabeads™
Published: 2023-09-06 (Crawled : 22:00) - biospace.com/
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
|
| O: -2.61%
H: 0.0%
C: 0.0%
cell therapy platform
Global RNA Therapy Clinical Trials Market Review 2022 and Forecast 2023-2030: Modality, Clinical Trials Phase, Therapeutic Areas, and Regional Business Analysis
Published: 2023-08-18 (Crawled : 22:00) - prnewswire.com
LH M | $201.48 1.02% 0.0% 770K
|
Health Services
| Email alert
Add to watchlist
CRL | $226.78 -0.34% 0.0% 410K
|
Commercial Services
| Email alert
Add to watchlist
MEDP | $371.87 -0.66% -0.66% 220K
|
Commercial Services
| Email alert
Add to watchlist
ICLR | $288.32 -1.2% -1.21% 640K
|
Health Technology
| Email alert
Add to watchlist
business review trials global therapy market
Global Viral & Non-Viral Vector Manufacturing Market 2023 to 2027: Growing Prominence of Gene and Cell Therapy Products Fuels the Sector
Published: 2023-07-03 (Crawled : 22:00) - prnewswire.com
LZAGY | $55.65 0.02% 32K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
CTLT | $55.48 -0.57% -0.4% 1.6M
|
Health Technology
| Email alert
Add to watchlist
TMO | News | $544.78 0.6% 0.0% 1.7M
|
Health Technology
| Email alert
Add to watchlist
DHR | $235.51 -0.36% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
LZAGF | $563.5 -19.1% 6
|
Health Technology
| Email alert
Add to watchlist
cell global growing therapy market
FDA Approves First Gene Therapy for Adults with Severe Hemophilia A
Published: 2023-06-29 (Crawled : 22:00) - fda.gov
BMRN | $88.68 -1.54% -1.57% 1.8M
|
Health Technology
|
| O: 1.2%
H: 1.97%
C: -3.69%
fda therapy
Occupational Therapy Software Market to grow by USD 87,435.59 thousand between 2022 to 2027; Growth opportunities led by Axis Teletherapy and Baylaan Technologies Inc- Technavio
Published: 2023-06-29 (Crawled : 22:00) - prnewswire.com
GPN | $122.1 -0.07% 0.0% 1.1M
|
Technology Services
|
| O: 1.23%
H: 1.34%
C: 0.37%
software therapy growth market
Orsini Selected by Sarepta Therapeutics to Dispense ELEVIDYS (delandistrogene moxeparvovec-rokl), the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Published: 2023-06-27 (Crawled : 22:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: -0.75%
H: 0.43%
C: -1.0%
treat therapeutics duchenne therapy
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy
Published: 2023-06-22 (Crawled : 22:00) - biospace.com/
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.06%
H: 2.73%
C: -2.39%
fda approval treat therapeutics duchenne therapy
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
Published: 2023-06-08 (Crawled : 22:00) - biospace.com/
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.28%
H: 0.42%
C: -0.05%
fda approval cell therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.